

# First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study

Angie Mae Rodday,<sup>1,2</sup> Theresa Hahn,<sup>3</sup>  
Anita J. Kumar,<sup>1,2</sup> Peter K. Lindenaue,<sup>4</sup>  
Jonathan W. Friedberg,<sup>5</sup> Andrew M.  
Evens<sup>6</sup> and Susan K. Parsons<sup>1,2</sup>

<sup>1</sup>Institute for Clinical Research and Health Policy Studies, Tufts Medical Center,

<sup>2</sup>Department of Medicine, Tufts University School of Medicine, Boston, MA, <sup>3</sup>Roswell Park Comprehensive Cancer Center,

Buffalo, NY, <sup>4</sup>Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School - Baystate, Springfield, MA, <sup>5</sup>Wilmot Cancer Institute, Rochester, NY and <sup>6</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Received 27 September 2019; accepted for publication 14 January 2020

Correspondence: Angie Mae Rodday, Tufts Medical Center, 800 Washington St #345, Boston, MA 02111, USA.

E-mail: arodday@tuftsmedicalcenter.org

## Summary

While Hodgkin lymphoma (HL) is highly curable in younger patients, older patients have higher relapse and death rates, which may reflect age-related factors, distinct disease biology and/or treatment decisions. We described the association between patient, disease and geographic factors and first-line treatment in older patients ( $\geq 65$  years) with incident HL using Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 1999 to 2014 ( $n = 2825$ ). First-line treatment initiated at  $\leq 4$  months after diagnosis was categorised as: full chemotherapy regimen ( $n = 699$ , 24.7%); partial chemotherapy regimen ( $n = 1016$ , 36.0%); single chemotherapy agent or radiotherapy ( $n = 382$ , 13.5%); and no treatment ( $n = 728$ , 25.8%). Among the fully treated, ABVD [doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine]/AVD was most common ( $n = 635$ , 90.8%). Adjusted multinomial logistic regression identified factors associated with treatment. Older age, Medicaid dual eligibility, not married, frailty, cardiac comorbidity, prior cancer, earlier diagnosis date, histology, advanced disease Stage, B symptoms and South region were independently associated with increased odds of not receiving full chemotherapy regimens. In conclusion, we found variability in first-line HL treatment for older patients. Treatment differences by Medicaid and region may indicate disparities. Even after adjusting for frailty and cardiac comorbidity, age was associated with treatment, suggesting factors such as end-of-life care or shared decision-making may influence treatment in older patients.

**Keywords:** Hodgkin disease, aged, antineoplastic agents, SEER programme, healthcare disparities.

Hodgkin lymphoma (HL) is a success story within haematological malignancies, with cure rates exceeding 85–90% in younger patients (National Cancer Institute; Evens, Sweetenham, & Horning, 2008; Appel *et al.*, 2012; Meyer *et al.*, 2012). First-line HL treatment typically includes multi-agent chemotherapy, such as ABVD [doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine], with or without radiotherapy (RT) (Duggan *et al.*, 2003; Hoppe *et al.*, 2012; National Comprehensive Cancer Network, 2019). Despite treatment success in younger patients, older patients aged  $>60$  or 65 years with HL have a 5-year overall survival of only 40–55% (Feltl, Vitek, & Zamecnik, 2006; Evens *et al.*, 2008).

Various factors influence first-line treatment choice in older patients with HL, including inability to tolerate multi-agent chemotherapy regimens, risk of toxicity from aggressive therapy due to comorbidities and/or frailty, differences in HL biology, patient preference and clinicians' reluctance to treat older patients as aggressively as younger patients (Evens *et al.*, 2008; Bjorkholm, Svedmyr, & Sjoberg, 2011; Parikh, Grossbard, Green, Harrison, & Yahalom, 2015; Reagan, Magnuson, & Friedberg, 2016). Previous guidelines on HL treatment from the National Comprehensive Cancer Network (NCCN) stated that 'individualized treatment may be necessary for older patients and patients with concomitant disease', while more recent guidelines have specific

recommendations for omitting certain drugs (e.g. bleomycin from ABVD) or using shorter courses or less toxic regimens (Hoppe *et al.*, 2012; National Comprehensive Cancer Network, 2019). In clinical practice, drugs may be omitted from the regimen, or patients may receive fewer cycles, dose reductions or dose omissions (Engert *et al.*, 2005; Evens *et al.*, 2008). Additionally, some older patients are treated with palliative approaches, such as single chemotherapy agents or limited-field RT (Boll *et al.*, 2013).

A challenge of studying older patients with HL is their underrepresentation in clinical trials (Engert *et al.*, 2005; Abbasi, 2019). Most older patients are treated in community oncology practices, with less access to clinical trials. Further, available data about treatment of older patients with HL are limited by small sample size, short follow-up, decreased generalisability to community practices or retrospective design (Ballova *et al.*, 2005; Evens *et al.*, 2008; Evens *et al.*, 2012; Evens *et al.*, 2013; Forero-Torres *et al.*, 2015; Friedberg *et al.*, 2017). Therefore, we lack understanding of first-line treatment, second-line treatment after treatment failure and the associated outcomes in older HL patients.

The use of a large, longitudinal population-level database that combines clinical and claims data, such as Surveillance, Epidemiology, and End Results (SEER)-Medicare, provides data on older patients, including those treated at community practices and survival outcomes. The present study describes which HL treatments are used and identifies whether patient, disease and geographic factors are associated with treatment choice. We hypothesised that older age, frailty, comorbidity and lower socio-economic status would be associated with less treatment with full, multi-agent chemotherapy regimens.

## Methods

### SEER-Medicare

SEER-Medicare data link two population-based databases with detailed information on Medicare beneficiaries with cancer (National Cancer Institute; Warren, Klabunde, Schrag, Bach, & Riley, 2002). SEER contains information from cancer registries, while Medicare data contains information on claims for healthcare services, including treatment, from time of entry into Medicare until death. SEER data come from population-based tumour registries from 17 regions, which collect information (e.g. demographics, date of diagnosis, Stage, histology) on newly diagnosed patients residing in those regions. Medicare is the national health insurance programme for Americans aged  $\geq 65$  years and a small subset aged  $< 65$  years who qualify based on disability status or certain medical conditions. Nearly all Medicare beneficiaries have Part A to cover hospital, skilled-nursing facility, hospice and home healthcare. Most are also enrolled in Part B to cover physician and outpatient services. The majority of beneficiaries have fee-for-service coverage, rather than Part C (also known as Medicare Advantage). Claims for Part C

services are not included in SEER-Medicare, so their healthcare service use cannot be determined. Part D is an optional outpatient prescription drug plan implemented in 2006 that covers approximately 70% of SEER-Medicare beneficiaries (National Cancer Institute). About 20% of Medicare beneficiaries are eligible for Medicaid based on low income (referred to as Medicaid dual eligibility) (Jacobson *et al.*, 2012).

### Sample

This retrospective cohort study utilised SEER-Medicare data from 1999 to 2014. Patients were aged  $\geq 65$  years at diagnosis with incident classical HL. The cohort was restricted to Medicare Part A and B fee-for-service coverage for 6 months prior to and 1 year after diagnosis (or until date of death) to fully capture claims for treatment. Exclusion criteria were: missing diagnosis month; unknown diagnostic confirmation; diagnosis reported from autopsy or death certificate; another cancer diagnosis  $< 6$  months before HL diagnosis; no claims within 6 months of diagnosis; and unknown Stage (Fig 1). Patients with only one to 10 claims within 6 months of diagnosis were reviewed for inclusion, and were required to have one or more HL-related claim(s). To understand potential differences by type of Medicare coverage, we compared available patient, disease and geographic factors by whether patients were enrolled in Medicare Part A and B (Table A1).

### First-line treatment

First-line treatment at  $\leq 4$  months of diagnosis was determined from inpatient, outpatient and physician/supplier claims using chemotherapy J-codes, Healthcare Common Procedure Coding System (HCPCS) codes and Diagnosis Related Group (DRG) codes and was categorised as: (i) full chemotherapy regimens (hereafter 'full regimen'); (ii) partial chemotherapy regimen (hereafter 'partial regimen'); (iii) single chemotherapy agent or RT (hereafter 'single agent/RT') or (iv) no claims for chemotherapy or RT (hereafter 'no treatment'). Full regimens were defined as the minimal number of cycles recommended for the patient's Stage (early or advanced) based on NCCN guidelines and established chemotherapy regimens for HL, even though some patients were treated prior to the issuance of these recommendations (Table A2) (Canellos *et al.*, 1992; Ballova *et al.*, 2005; Boll *et al.*, 2011; Hoppe *et al.*, 2012; Gordon *et al.*, 2013; National Comprehensive Cancer Network, 2019). To be classified as having received a full regimen, patients had to receive all drugs for the recommended number of cycles, but were allowed to miss one administration of one drug. Orally administered drugs (e.g. steroids, procarbazine) were not required for full regimens because they were only available in Part D pharmacy claims. Information on dose modifications was not available. Partial regimens included any multi-agent chemotherapy regimen that did not meet full regimen criteria. Single agent/RT included patients treated with one




Fig 1. HL cohort development.

chemotherapy agent at a time and/or RT. No treatment was defined by lack of claims for chemotherapy or RT within 4 months of diagnosis.

### Covariates

Patient and disease characteristics were defined based on SEER registry or Medicare data. Follow-up duration was defined as the number of months (from diagnosis) until the earliest of the following: death; end of continuous Medicare Part A and B fee-for-service enrolment; or the end of the available data (31/12/2014). Diagnosis date, age at diagnosis, gender, race/ethnicity, marital status, HL histology, Ann Arbor Stage and B symptoms were defined from SEER registry data. Medicaid dual eligibility was defined using the

State ‘buy-in’ indicator. Frailty and comorbidity were defined using validated claims-based algorithms recorded in the 6 months prior to HL diagnosis (Quan *et al.*, 2005; Segal *et al.*, 2017). Based on published data, frailty was defined by a probability score of  $\geq 0.12$  (Segal *et al.*, 2017). The current HL cancer was excluded from the comorbidity index. A separate cardiac comorbidity indicator was created for myocardial infarction or congestive heart failure, based on their hypothesised relationship with treatment choice. Prior cancer was defined as having a SEER-Medicare entry for any cancer >6 months prior to HL diagnosis. Missing data from the SEER registry or Medicare enrolment data are typically classified as unknown. These patients were included in analyses (except for unknown Stage), either as a separate category or collapsed with other small categories.

Geographic characteristics included region, population density and presence of a hospital providing chemotherapy within the health service area (HSA). Region and population density were determined from the Medicare enrolment file based on Zip Code. Population density was dichotomised into more populated (big metro, metro, urban) and less populated (less urban, rural). Regions included Northeast, Midwest, South and West based on SEER-registry data using Census Region Codes. The 2017–2018 Area Health Resources Files (AHRF) Access System was used to determine whether there was a hospital providing chemotherapy in the HSA during the year of HL diagnosis. Federal Information Processing Standards (FIPS) county and State codes provided the linkage between SEER-Medicare and AHRF data, using the SEER-Medicare HSA definition (National Cancer Institute).

### Statistical analysis

Patient, disease and geographic characteristics were described for the whole sample and separately by first-line treatment. To further understand why patients did not receive treatment by 4 months, we explored the use of any treatment, use of hospice or death by 12 months after diagnosis (Table A3). We then described patient, disease and geographic characteristics for this group compared with treated patients (Table A4). Cell counts of <11 were suppressed and other cells were coarsened to avoid re-identification of patients in accordance with SEER-Medicare policy (Research Data Assistance Center, 2017).

Multinomial logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) to identify factors associated with first-line treatment. Univariate models between first-line treatment and all patient, disease and geographic characteristics were first estimated. A multivariable model that included all characteristics was then estimated to adjust for potential confounding between variables. Two-way interactions between age, Stage, frailty and cardiac comorbidity were added to a separate adjusted multivariable model based on our hypothesis that these factors would modify each other's effect on treatment. Backwards elimination based on  $P < 0.05$  was used to remove non-significant interaction terms. To understand the difference in the probability of each treatment category based on the non-interaction and interaction models, we used least square means to estimate the probability of each treatment category for specified levels of the interaction variables (e.g. early or advanced Stage; cardiac comorbidity or not; age 65, 75, 85 years); other variables were set to their reference or mean values. Model fit was assessed by examining potential influence points, linearity of continuous variables and collinearity (using variance inflation factors). Data were analysed using the Statistical Analysis System (SAS) Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, USA).

## Results

### Sample

The cohort included 2825 patients diagnosed with HL, aged  $\geq 65$  years, who met eligibility criteria (Fig 1). The mean (SD, maximum) age was 76.0 (7.0, 98) years, 50.0% were female, 83.7% were White/non-Hispanic and 13.8% were Medicaid dual eligible (Table I). Over half (51.1%) met criteria for frailty, 78.7% had at least one comorbidity, 26.2% had a cardiac comorbidity and 15.9% had a prior cancer. The most common HL histology was nodular sclerosis (36.7%), patients were evenly distributed across Stage and 36.4% had B symptoms. Nearly all patients (95.5%) lived in an area with a hospital that provided chemotherapy. Patients had a median (interquartile range [IQR] Q1–Q3) of 21 (5–59) months of eligible follow-up and 1071 (37.9%) died by 12 months after diagnosis.

### First-line treatment

Patients were classified into the following categories: 699 (24.7%) received full regimens, 1016 (36.0%) received partial regimens, 382 (13.5%) received a single agent/RT and 728 (25.8%) received no documented treatment. Among those receiving full regimens, 635 (90.8%) received ABVD/AVD (Table II). Among untreated patients ( $n = 728$ ), 602 (82.7%) had an explanation for no treatment by 12 months (Table A3). For example, 90 (12.4%) died within the month of diagnosis, while 199 (27.3%) received hospice care by 6 months.

### Factors associated with first-line treatment

Univariate multinomial logistic regression indicated that the following factors were significantly associated with first-line treatment: age, marital status, Medicaid dual eligibility, frailty, cardiac comorbidity, prior cancer, diagnosis year, histology, Stage and B symptoms (Table III). Race/ethnicity, region, population density and hospitals providing chemotherapy were not associated with treatment.

In adjusted analysis comparing treatment with partial regimens to full regimens (Table III), frailty (OR 1.53, 95% CI 1.12–2.09), cardiac comorbidity (OR 1.67, 95% CI 1.23–2.25), not otherwise specified (NOS) histology (OR 1.35 vs. nodular sclerosis, 95% CI 1.04–1.76), advanced Stage (OR 8.60, 95% CI 6.79–10.90) and South region (OR 1.45 vs. West, 95% CI 1.07–1.97) were associated with higher odds of treatment with partial regimens compared with full regimens. More recent diagnostic year (OR 0.93, 95% CI 0.90–0.96) was associated with lower odds of treatment with partial regimens compared with full regimens.

In adjusted analysis comparing treatment with single agent/RT to full regimens (Table III), older age (OR 1.75 per 5-year increase, 95% CI 1.52–2.01), frailty (OR 1.76, 95% CI

**Table I.** Characteristics of patients at HL diagnosis by first-line treatment, *n* = 2825.

	Overall, <i>n</i> = 2825	Full regimen, <i>n</i> = 699	Partial regimen, <i>n</i> = 1016	Single agent/RT, <i>n</i> = 382	No treatment*, <i>n</i> = 728
<b>Patient factors</b>					
Age, years, mean (SD)	76 (7.0)	73.3 (5.9)	74.9 (6.2)	79.3 (7.2)	78.2 (7.4)
Age categorical, <i>n</i> (%)					
65–69 years	619 (21.9)	225 (32.2)	242 (23.8)	40 (10.5)	112 (15.4)
70–74 years	671 (23.8)	204 (29.2)	265 (26.1)	69 (18.1)	133 (18.3)
75–79 years	654 (23.2)	157 (22.5)	262 (25.8)	79 (20.7)	156 (21.4)
≥80 years	881 (31.2)	113 (16.2)	247 (24.3)	194 (50.8)	327 (44.9)
Female, <i>n</i> (%)	1413 (50.0)	364 (52.1)	489 (48.1)	206 (53.9)	354 (48.6)
Race/ethnicity, <i>n</i> (%)					
White/non-Hispanic	2364 (83.7)	596 (85.3)	863 (84.9)	>320 (>83.8)†	583 (80.1)
Black/non-Hispanic	143 (5.1)	34 (4.9)	36 (3.5)	21 (5.5)	52 (7.1)
Hispanic	233 (8.3)	47 (6.7)	91 (9)	30 (7.9)	65 (8.9)
Other race/non-Hispanic	85 (3.0)	22 (3.2)	26 (2.6)	†	28 (3.9)
Marital status, <i>n</i> (%)					
Married	1601 (56.7)	443 (63.4)	621 (61.1)	203 (53.1)	334 (45.9)
Single/widowed/unknown	1224 (43.3)	256 (36.6)	395 (38.9)	179 (46.9)	394 (54.1)
Medicaid dual enrolled, <i>n</i> (%)	389 (13.8)	71 (10.2)	138 (13.6)	45 (11.8)	135 (18.5)
Frailty, <i>n</i> (%)	1443 (51.1)	205 (29.3)	474 (46.7)	260 (68.1)	504 (69.2)
Comorbidity, <i>n</i> (%)	2224 (78.7)	497 (71.1)	812 (79.9)	293 (76.7)	622 (85.4)
Cardiac comorbidity, <i>n</i> (%)	740 (26.2)	94 (13.5)	247 (24.3)	114 (29.8)	285 (39.2)
Prior cancer, <i>n</i> (%)	450 (15.9)	98 (14)	165 (16.2)	80 (20.9)	107 (14.7)
<b>Disease factors</b>					
Diagnosis year, <i>n</i> (%)					
2000–2004	909 (32.2)	190 (27.2)	321 (31.6)	163 (42.7)	235 (32.3)
2005–2009	1132 (40.1)	318 (45.5)	393 (38.7)	138 (36.1)	283 (38.9)
2010–2013	784 (27.8)	191 (27.3)	302 (29.7)	81 (21.2)	210 (28.9)
Histology, <i>n</i> (%)					
Nodular Sclerosis	1036 (36.7)	310 (44.4)	364 (35.8)	>143 (>37.4)†	209 (28.7)
Mixed cellularity	593 (21.0)	150 (21.5)	231 (22.7)	70 (18.3)	142 (19.5)
Lymphocyte rich	122 (4.3)	31 (4.4)	33 (3.3)	37 (9.7)	21 (2.9)
Lymphocyte depleted	92 (3.3)	15 (2.2)	38 (3.7)	†	38 (5.2)
NOS	982 (34.8)	193 (27.6)	350 (34.5)	121 (31.7)	318 (43.7)
Ann Arbor Stage, <i>n</i> (%)					
I	663 (23.5)	239 (34.2)	114 (11.2)	156 (40.8)	154 (21.2)
II	670 (23.7)	282 (40.3)	146 (14.4)	96 (25.1)	146 (20.1)
III	767 (27.2)	94 (13.5)	413 (40.7)	65 (17)	195 (26.8)
IV	725 (25.7)	84 (12)	343 (33.8)	65 (17)	233 (32)
B symptoms, <i>n</i> (%)					
No	1167 (41.3)	346 (49.5)	362 (35.6)	207 (54.2)	252 (34.6)
Yes	1027 (36.4)	191 (27.3)	451 (44.4)	97 (25.4)	288 (39.6)
Unknown	631 (22.3)	162 (23.2)	203 (20)	78 (20.4)	188 (25.8)
<b>Geographic factors</b>					
Region, <i>n</i> (%)					
Northeast	659 (23.3)	151 (21.6)	242 (23.8)	87 (22.8)	179 (24.6)
Midwest	390 (13.8)	114 (16.3)	124 (12.2)	59 (15.5)	93 (12.8)
South	685 (24.3)	154 (22)	256 (25.2)	91 (23.8)	184 (25.3)
West	1091 (38.6)	280 (40.1)	394 (38.8)	145 (38)	272 (37.4)
Urban/rural, <i>n</i> (%)					
More populated	2498 (88.4)	618 (88.4)	903 (88.9)	334 (87.4)	643 (88.3)
Less populated	327 (11.6)	81 (11.6)	113 (11.1)	48 (12.6)	85 (11.7)
Hospital with chemotherapy, <i>n</i> (%)	2698 (95.5)	669 (95.7)	971 (95.6)	369 (96.6)	689 (94.6)

NOS, not otherwise specified.

\*No treatment refers to no claims for chemotherapy or RT.

†Cell counts &lt;11 were suppressed and other cells were coarsened to avoid re-identification of patients in accordance with SEER-Medicare policy



**Table II.** Treatment details for patients receiving any first-line treatment,  $n = 2097$ .

Treatment	$n$ (%) <sup>*</sup>
Full chemotherapy regimen	699
Full ABVD/AVD	635 (90.8)
Full BEACOPP	†
Full CHOP	†
Full COPP	27 (3.9)
Full MOPP	†
Full PVAG	†
Full Stanford V	22 (3.1)
Full VEPEMB	†
Partial chemotherapy regimen	1016
Partial chemotherapy regimen	1016 (100)
Single chemotherapy agent or RT	382
Single chemotherapy agent only	147 (38.5)
RT only	>244 (>58.6)†
Both	†

<sup>\*</sup>Denominator for specific treatment is the number in the overall treatment category.

†Cell counts < 11 were suppressed and other cells were coarsened to avoid re-identification of patients in accordance with SEER-Medicare policy.

1.19–2.60), cardiac comorbidity (OR 2.16, 95% CI 1.53–3.07), prior cancer (OR 1.83, 95% CI 1.28–2.62), lymphocyte-rich histology (OR 3.23 vs. nodular sclerosis, 95% CI 1.84–5.69) and advanced Stage (OR 1.89, 95% CI 1.40–2.55) were associated with higher odds of treatment with single agent/RT compared with full regimens. More recent diagnostic year (OR 0.87, 95% CI 0.83–0.90), lymphocyte-depleted histology (OR 0.12 vs. nodular sclerosis, 95% CI 0.02–0.93) and B symptoms (OR 0.70, 95% CI 0.51–0.98) were associated with lower odds of treatment with single agent/RT compared with full regimens.

In adjusted analysis comparing treatment with no treatment to full regimens (Table III), older age (OR 1.50 per 5-year increase, 95% CI 1.33–1.69), Medicaid dual eligibility (OR 1.62, 95% CI 1.10–2.39), frailty (OR 1.82, 95% CI 1.30–2.54), cardiac comorbidity (OR 2.95, 95% CI 2.18–4.00), lymphocyte-depleted histology (OR 2.64 vs. nodular sclerosis, 95% CI 1.32–5.28), NOS histology (OR 2.22 vs. nodular sclerosis, 95% CI 1.67–2.94), advanced Stage (OR 4.12, 95% CI 3.20–5.31), B symptoms (OR 1.34, 95% CI 1.01–1.77) and South region (OR 1.41 vs. West, 95% CI 1.01–1.98) were associated with higher odds of no treatment compared with full regimens. Being married (OR 0.71, 95% CI 0.56–0.91) and more recent diagnostic year (OR 0.93, 95% CI 0.90–0.96) were associated with lower odds of no treatment compared with full regimens.

We found significant two-way interactions between Stage and cardiac comorbidity ( $P = 0.03$ ), as well as Stage and age ( $P = 0.003$ ). A visual comparison of treatment probability based on least square means from the adjusted models with and without these interaction terms demonstrate few

differences in the effect of Stage, age and cardiac comorbidity, when allowed to vary in the interaction model (Fig A1). That is, a comparison between the left (no interactions) and right (interactions) panels for a given age demonstrate similar probabilities of treatment for a given combination of Stage and cardiac comorbidity. Model assessment indicated no influence points, no violations of linearity and no collinearity.

## Discussion

We present a large population-based analysis to evaluate first-line treatment amongst older adults with HL. One-quarter received full chemotherapy regimens, with ABVD/AVD being the most common, consistent with previously reported practices in the USA (Santoro *et al.*, 1987; Evens *et al.*, 2012). A substantial proportion of patients received AVD without bleomycin, probably due to existing comorbidities or fear of toxicity (Evens *et al.*, 2013). In addition, we observed more aggressive treatment in recent years, perhaps reflecting less reluctance to treat older patients aggressively if they are able to tolerate treatment. Although only approved as first-line treatment after our study window, future research should study the use of brentuximab vedotin, which has shown preliminary tolerability and efficacy in older patients (Friedberg *et al.*, 2017; Connors *et al.*, 2018; Evens *et al.*, 2018).

Wide variability in treatment of HL in older patients was observed. Based on our present analysis, this variability may not be fully explained by patient or disease factors, highlighting challenges in treating this patient population. Further, we found treatment differences by geographic region, which may reflect undesirable variation in care delivery and outcomes (Onega *et al.*, 2008; Keating *et al.*, 2018). The remaining variability in treatment selection, particularly palliative treatment (single chemotherapy agent or RT) or no documented treatment with chemotherapy or RT, may be explained by patient-provider shared decision-making and patient or family preferences, especially at the end-of-life (Zhang & Siminoff, 2003). We found that married patients were more likely to receive full regimens, possibly as a marker of social support or the influence of family in treatment choices (Aizer *et al.*, 2013).

Similar to prior research in HL and other cancers, age influenced treatment choice (Evens *et al.*, 2008; Given & Given, 2008; Bjorkholm *et al.*, 2011). However, this was not fully explained by frailty or cardiac comorbidity given that the association between age and treatment remained significant after adjustment for these and other factors. This further highlights the role that shared decision-making and patient preference may play in treatment selection. In addition, frailty and cardiac comorbidity informed treatment. Frailty is caused by cumulative declines across multiple systems, which leads to decreased reserves, less resistance to stressors and ultimately, adverse outcomes (Fried *et al.*, 2001). Typically, both frailty and presence of comorbidities increase with age,

Table III. Multinomial logistic regression model of first-line treatment, *n* = 2825.

	Univariate, OR (95% CI)			Multivariable, OR (95% CI)		
	Partial regimen vs. full regimen	Single agent/RT vs. full regimen	No treatment <sup>a</sup> vs. full regimen	Partial regimen vs. full regimen	Single agent/RT vs. full regimen	No treatment <sup>a</sup> vs. full regimen
<b>Patient factors</b>						
Age (per 5-year increase)	<b>1.23 (1.14–1.33)</b>	<b>1.96 (1.78–2.16)</b>	<b>1.75 (1.61–1.91)</b>	1.11 (1.00–1.25)	<b>1.75 (1.52–2.01)</b>	<b>1.50 (1.33–1.69)</b>
Race/ethnicity						
White/non-Hispanic	Ref	Ref	Ref	Ref	Ref	Ref
Black/non-Hispanic	0.73 (0.45–1.18)	1.14 (0.65–2.00)	1.56 (1.00–2.44)	0.66 (0.38–1.14)	1.30 (0.70–2.43)	1.45 (0.86–2.46)
Hispanic	1.34 (0.93–1.93)	1.18 (0.73–1.91)	1.41 (0.96–2.09)	1.20 (0.76–1.89)	1.46 (0.82–2.60)	1.31 (0.81–2.13)
Other race/non-Hispanic	0.82 (0.46–1.45)	0.76 (0.35–1.66)	1.30 (0.74–2.30)	0.69 (0.35–1.34)	0.91 (0.38–2.19)	1.20 (0.61–2.35)
Marital status						
Married	0.91 (0.75–1.11)	<b>0.66 (0.51–0.84)</b>	<b>0.49 (0.40–0.61)</b>	1.02 (0.81–1.29)	0.96 (0.72–1.28)	<b>0.71 (0.56–0.91)</b>
Single/widowed/unknown	Ref	Ref	Ref	Ref	Ref	Ref
Medicaid dual eligible	<b>1.39 (1.03–1.89)</b>	1.18 (0.80–1.76)	<b>2.01 (1.48–2.74)</b>	1.31 (0.90–1.92)	1.09 (0.68–1.77)	<b>1.62 (1.10–2.39)</b>
Frailty	<b>2.11 (1.72–2.59)</b>	<b>5.14 (3.92–6.73)</b>	<b>5.42 (4.32–6.80)</b>	<b>1.53 (1.12–2.09)</b>	<b>1.76 (1.19–2.60)</b>	<b>1.82 (1.30–2.54)</b>
Cardiac comorbidity	<b>2.07 (1.59–2.68)</b>	<b>2.74 (2.01–3.73)</b>	<b>4.14 (3.18–5.39)</b>	<b>1.67 (1.23–2.25)</b>	<b>2.16 (1.53–3.07)</b>	<b>2.95 (2.18–4.00)</b>
Prior cancer	1.19 (0.91–1.56)	<b>1.63 (1.17–2.25)</b>	1.06 (0.79–1.42)	1.35 (0.99–1.82)	<b>1.83 (1.28–2.62)</b>	1.17 (0.84–1.63)
<b>Disease factors</b>						
Diagnosis year	0.98 (0.95–1.00)	<b>0.91 (0.88–0.95)</b>	<b>0.97 (0.94–1.00)</b>	<b>0.93 (0.90–0.96)</b>	<b>0.87 (0.83–0.90)</b>	<b>0.93 (0.90–0.96)</b>
<b>Histology</b>						
Nodular sclerosis	Ref	Ref	Ref	Ref	Ref	Ref
Mixed cellularity	<b>1.31 (1.02–1.69)</b>	0.95 (0.67–1.33)	<b>1.40 (1.05–1.87)</b>	1.32 (0.99–1.76)	0.86 (0.59–1.25)	1.36 (0.99–1.88)
Lymphocyte depleted	<b>2.16 (1.17–4.00)</b>	0.14 (0.02–1.03)	<b>3.76 (2.02–7.01)</b>	1.61 (0.82–3.18)	<b>0.12 (0.02–0.93)</b>	<b>2.64 (1.32–5.28)</b>
Lymphocyte rich	0.91 (0.54–1.51)	<b>2.42 (1.45–4.05)</b>	1.01 (0.56–1.80)	1.51 (0.86–2.64)	<b>3.23 (1.84–5.69)</b>	1.51 (0.81–2.83)
NOS	<b>1.54 (1.23–1.95)</b>	1.27 (0.94–1.71)	<b>2.44 (1.90–3.14)</b>	<b>1.35 (1.04–1.76)</b>	1.29 (0.93–1.78)	<b>2.22 (1.67–2.94)</b>
<b>Ann Arbor Stage</b>						
Early (I/II)	Ref	Ref	Ref	Ref	Ref	Ref
Advanced (III/IV)	<b>8.51 (6.82–10.62)</b>	<b>1.51 (1.15–1.98)</b>	<b>4.18 (3.33–5.23)</b>	<b>8.60 (6.79–10.90)</b>	<b>1.89 (1.40–2.55)</b>	<b>4.12 (3.20–5.31)</b>
<b>B symptoms</b>						
No	Ref	Ref	Ref	Ref	Ref	Ref
Yes	<b>2.26 (1.80–2.82)</b>	0.85 (0.63–1.15)	<b>2.07 (1.62–2.64)</b>	1.27 (0.98–1.63)	<b>0.70 (0.51–0.98)</b>	<b>1.34 (1.01–1.77)</b>
Unknown	1.20 (0.93–1.54)	0.81 (0.58–1.11)	<b>1.59 (1.22–2.08)</b>	0.99 (0.74–1.32)	<b>0.61 (0.43–0.88)</b>	1.32 (0.97–1.78)
<b>Geographic factors</b>						
Region						
Northeast	1.14 (0.88–1.47)	1.11 (0.80–1.55)	1.22 (0.93–1.60)	1.34 (1.00–1.79)	1.15 (0.79–1.66)	1.35 (0.98–1.85)
Midwest	0.77 (0.57–1.04)	1.00 (0.69–1.45)	0.84 (0.61–1.16)	0.76 (0.53–1.08)	0.88 (0.57–1.35)	0.78 (0.53–1.15)
South	1.18 (0.92–1.52)	1.14 (0.82–1.58)	1.23 (0.94–1.61)	<b>1.45 (1.07–1.97)</b>	1.25 (0.85–1.85)	<b>1.41 (1.01–1.98)</b>
West	Ref	Ref	Ref	Ref	Ref	Ref
Less populated	0.96 (0.71–1.29)	1.10 (0.75–1.61)	1.01 (0.73–1.39)	1.04 (0.72–1.50)	1.37 (0.87–2.14)	1.22 (0.82–1.81)
Hospital with chemotherapy	1.03 (0.64–1.66)	0.79 (0.41–1.53)	1.26 (0.78–2.06)	1.07 (0.62–1.84)	1.37 (0.66–2.86)	0.90 (0.51–1.59)

NOS, not otherwise specified.

Bolding indicates *P* < 0.05.

\*No treatment refers to no claims for chemotherapy or RT.

reducing patients' ability to tolerate treatment with full chemotherapy regimens.

We found evidence of disparities in treatment of patients with Medicaid dual eligibility, who were more likely to receive no treatment. Given that Medicaid is the payer of last resort, we would not expect a lack of treatment claims if a patient with Medicaid dual eligibility actually received treatment (Social Security, 1965). As these results adjusted for other patient, disease and geographic factors, these suggest a possible disparity in care, similar to those observed in many health conditions (Institute of Medicine, 2003; Kawachi, Daniels, & Robinson, 2005; Warren *et al.*, 2015; Popescu, Schrag, Ang, & Wong, 2016). Patients who are Medicaid dual eligibility may be sicker and have spent more money on healthcare (referred to as 'spend down'), thereby qualifying for dual eligibility. Although Medicaid dual eligibility has reduced cost sharing, which may eliminate some cost-related barriers to care, there is evidence that patients who are dual eligible are sicker, have more comorbidities (including mental health issues) and face other socio-economic challenges (The Kaiser Commission on Medicaid & the Uninsured, 2010; Medicare Payment Advisory Committee & Medicaid and CHIP Payment and Access Commission, 2018). Further, there is evidence of problems with care coordination for dual eligible beneficiaries and worse outcomes for Medicaid beneficiaries (Cassidy, 2012; Gold, Jacobson, & Garfield, 2012; Parikh *et al.*, 2015). To improve care, disparities need to be addressed and care coordination needs to be improved for patients who are dual eligible.

We acknowledge the present study's limitations. Although SEER-Medicare is the largest longitudinal population-based database of older adults with cancer, patients in the database are not necessarily representative of all older patients with cancer (e.g. elderly in SEER regions are less White, have lower poverty, live in urban areas, have lower cancer mortality) (Warren *et al.*, 2002). In order to determine first-line treatment using claims data, patients were limited to those with Medicare Part A and B fee-for-service, therefore limiting generalisability by excluding patients without fee-for-service (i.e. Medicare Advantage). Similar to prior research, we found some differences in Part A and B enrolment by age, race/ethnicity, Medicaid dual eligibility, urban/rural and region (Neuman & Jacobson, 2018). However, there were minimal differences by disease factors (e.g. histology, Stage) and death by 12 months. The SEER registry provided information on some disease factors (e.g. Stage, B symptoms), but other factors, such as prognostic score or bulk, are not collected. Further, some patients have unknown status on available disease factors, which may be directly related to the treatment decisions (e.g. biopsy to determine histology not performed in patients receiving end-of-life care). Treatment misclassification is possible when using claims data, especially for no treatment, which was assumed based on the lack of any treatment-related claims. However, we were able to

identify reasons for no treatment for nearly 82.7% of this group, therefore strengthening our confidence in treatment assignment. In addition, some patients classified as receiving partial regimens may have died before they were able to receive full regimens, but we estimate this as <18% (data not shown). Similarly, patients with advanced stage disease required more cycles for full chemotherapy regimens, which may partly explain why they were less likely to receive full regimens than patients with early stage disease.

In conclusion, one-quarter of older patients with HL received first-line treatment with full chemotherapy regimens. We found that factors such as age, frailty and cardiac comorbidity were associated with receipt of less aggressive or no treatment. Differences in treatment by insurance coverage and geography are disparities that need to be addressed, particularly as novel agents become available. Future research will link these treatments to clinical outcomes to better understand survival differences between older and younger patients and to identify opportunities to improve outcomes.

## Acknowledgements

We thank Nicole Savidge for her assistance with manuscript preparation.

## Funding

This project was supported by the National Center for Advancing Translational Sciences Award Number 1KL2TR002545 (Angie Mae Rodday) and National Heart, Lung, and Blood Institute Award Number K24HL132008 (Peter K. Lindenauer).

## Conflicts of interest

Angie Mae Rodday, Theresa Hahn, Anita J. Kumar, Peter K. Lindenauer and Susan K. Parsons: None. Jonathan W. Friedberg: Bayer (Honoraria; Data and Safety Monitoring Committee); Acerta (Data and Safety Monitoring Committee). Andrew M. Evens: Seattle Genetics (Scientific Advisory Board—Research Related); Epizyme (Scientific Advisory Board—Research Related); Novartis (Consultant—Data and Safety Monitoring Board); Pharmacyclis Novartis (Consultant—Data and Safety Monitoring Board).

## Author contributions

Angie Mae Rodday: Conceptualised project; performed and interpreted analysis; obtained funding; wrote draft. Theresa Hahn, Peter K. Lindenauer and Susan K. Parsons: Conceptualised project; interpreted analysis; obtained funding; edited draft. Anita J. Kumar, Jonathan W. Friedberg and Andrew M. Evens: Conceptualised project; interpreted analysis; edited draft.



**Appendix A**




Fig A1. Probability of first-line treatment based on least square means from adjusted multinomial logistic regression models with and without interactions<sup>a</sup>, *n* = 2825. <sup>a</sup>Probabilities estimated for the following levels of the interaction variables: early or advanced Stage; cardiac comorbidity or not; age 65, 75, 85 years. Other variables set to reference or mean values. No treatment refers to no claims for chemotherapy or RT.

Table A1. Characteristics of patients at HL diagnosis by information enrolment in Medicare Part A and B, *n* = 4725

Characteristic	Not enrolled in part A and B, <i>n</i> = 1696	Enrolled in part A and B, <i>n</i> = 3028	<i>P</i>
<b>Patient factors</b>			
Age, years, mean (SD)	74.2 (7.1)	76.0 (7.0)	<0.001
Female, <i>n</i> (%)	758 (44.7)	1507 (49.8)	<0.001
Race/ethnicity, <i>n</i> (%)			
White/non-Hispanic	1232 (72.6)	2516 (83.1)	<0.001
Black/non-Hispanic	276 (16.3)	259 (8.6)	
Hispanic	95 (5.6)	152 (5.0)	
Other race/non-Hispanic	93 (5.5)	101 (3.3)	
Marital status, <i>n</i> (%)			
Married	1002 (59.1)	1685 (55.7)	0.02
Single/widowed/unknown	694 (40.9)	1343 (44.4)	
Medicaid dual enrolled, <i>n</i> (%)	180 (10.6)	416 (13.7)	0.002
Prior cancer, <i>n</i> (%)	228 (13.4)	481 (15.9)	0.02
<b>Disease factors</b>			
Year of diagnosis, <i>n</i> (%)			
2000–2004	596 (35.1)	974 (32.2)	<0.001
2005–2009	585 (34.5)	1221 (40.3)	
2010–20013	515 (30.4)	833 (27.5)	
Histology, <i>n</i> (%)			
Nodular sclerosis	607 (35.8)	1109 (36.6)	0.50
Mixed cellularity	363 (21.4)	633 (20.9)	
Lymphocyte rich	81 (4.8)	127 (4.2)	
Lymphocyte depleted	41 (2.4)	96 (3.2)	
NOS	604 (35.6)	1063 (35.1)	
Ann Arbor Stage, <i>n</i> (%)			
I	349 (20.6)	666 (22.0)	0.73
II	375 (22.1)	676 (22.3)	
III	435 (25.7)	778 (25.7)	
IV	432 (25.5)	728 (24.0)	
Unknown	105 (6.2)	180 (5.9)	
B symptoms, <i>n</i> (%)			
No	725 (42.8)	1208 (39.9)	0.04
Yes	596 (35.1)	1060 (35.0)	
Unknown	375 (22.1)	760 (25.1)	
Died by 12 months	605 (35.7)	1137 (37.6)	0.20
<b>Geographic factors</b>			
Region, <i>n</i> (%)			
Northeast	213 (12.6)	714 (23.6)	<0.001
Midwest	113 (6.7)	400 (13.2)	
South	224 (13.2)	715 (23.6)	
West	1146 (67.6)	1199 (39.6)	
Urban/rural, <i>n</i> (%)			
More populated	1636 (96.5)	2684 (88.6)	<0.001
Less populated	59 (3.5)	344 (11.4)	

NOS, not otherwise specified.

Table A2. Definition of full chemotherapy regimens

Regimen	Drugs	Cycles required		Notes
		Early Stage	Advanced Stage	
ABVD/AVD	Doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine	2	6	Bleomycin not required to be considered full
BEACOPP	Bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone	4	6	Procarbazine and prednisone not required to be considered full because orally administered
CHOP	Cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), prednisone	4	6	Prednisone not required to be considered full because orally administered
COPP	Cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone	4	6	Procarbazine and prednisone not required to be considered full because orally administered
MOPP	Mechlorethamine, vincristine (Oncovin), procarbazine, prednisone	4	6	Procarbazine and prednisone not required to be considered full because orally administered
PVAG	Prednisone, vinblastine, doxorubicin (Adriamycin), gemcitabine	4	6	Prednisone not required to be considered full because orally administered
Stanford V	Mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, prednisone	2	3	Prednisone not required to be considered full because orally administered
VEPEMB	Vinblastine, cyclophosphamide, prednisolone, procarbazine, etoposide, mitoxantrone and bleomycin	4	6	Procarbazine, prednisone, and etoposide not required to be considered full because orally administered

References: Canellos *et al.*, 1992; Ballova *et al.*, 2005; Boll *et al.*, 2011; Hoppe *et al.*, 2012; Gordon *et al.*, 2013; National Comprehensive Cancer Network, 2019.

Table A3. Understanding patients with no treatment,  $n = 728$ 

	Sequential classification*, $n$ (%)	All classification†, $n$ (%)	Cumulative total,‡ $n$
Died within month of diagnosis	90 (12.4)	90 (12.4)	90
Received treatment by 6 months	81 (11.1)	81 (11.1)	171
Received hospice by 6 months	172 (23.6)	199 (27.3)	343
Died by 6 months	183 (25.1)	426 (58.5)	526
Received treatment by 12 months	31 (4.3)	112 (15.4)	557
Received hospice by 12 months	21 (2.9)	226 (31.0)	578
Died by 12 months	24 (3.3)	501 (68.8)	602
Unknown reason	126 (17.3)	126 (17.3)	728

\*Patients are assigned to the group in which they first appear; patients may only be counted once.

†Patients are assigned to any group to which they belong; patients may be counted more than once.

‡Patients from the sequential classification column are successively added to create the cumulative total.

**Table A4.** Characteristics of patients at HL diagnosis by information about first-line treatment by 12 months, *n* = 2825

Characteristic	Any treatment, <i>n</i> = 2097	Some treatment explanation by 12 months, <i>n</i> = 602	No treatment information by 12 months*, <i>n</i> = 126
<b>Patient factors</b>			
Age, years, mean (SD)	75.2 (6.6)	78.7 (7.3)	76.1 (7.6)
Age categorical, <i>n</i> (%)			
65–69 years	507 (24.2)	81 (13.5)	31 (24.6)
70–74 years	538 (25.7)	102 (16.9)	31 (24.6)
75–79 years	498 (23.8)	135 (22.4)	21 (16.7)
≥80 years	554 (26.4)	284 (47.2)	43 (34.1)
Female, <i>n</i> (%)	1059 (50.5)	300 (49.8)	54 (42.9)
Race/ethnicity, <i>n</i> (%)			
White/non-Hispanic	1781 (84.9)	480 (79.7)	103 (81.8)
Black/non-Hispanic	91 (4.3)	41 (6.8)	11 (8.7)
Hispanic	168 (8.0)	57 (9.5)	†
Other race/non-Hispanic	57 (2.7)	24 (4.0)	†
Marital status, <i>n</i> (%)			
Married	1267 (60.4)	261 (43.4)	73 (57.9)
Single/Widowed/Unknown	830 (39.6)	341 (56.6)	53 (42.1)
Medicaid dual enrolled, <i>n</i> (%)	254 (12.1)	117 (19.4)	18 (14.3)
Frailty, <i>n</i> (%)	939 (44.8)	448 (74.4)	56 (44.4)
Comorbidity, <i>n</i> (%)	1602 (76.4)	533 (88.5)	89 (70.6)
Cardiac comorbidity, <i>n</i> (%)	455 (21.7)	253 (42.0)	32 (25.4)
Prior cancer, <i>n</i> (%)	343 (16.4)	83 (13.8)	24 (19.1)
<b>Disease factors</b>			
Year of diagnosis, <i>n</i> (%)			
2000–2004	674 (32.1)	188 (31.2)	47 (37.3)
2005–2009	849 (40.5)	242 (40.2)	41 (32.5)
2010–20013	574 (27.4)	172 (28.6)	38 (30.2)
Histology, <i>n</i> (%)			
Nodular sclerosis	827 (39.4)	175 (29.1)	34 (27.0)
Mixed cellularity	451 (21.5)	115 (19.1)	27 (21.4)
Lymphocyte rich	101 (4.8)	12 (2.0)	†
Lymphocyte depleted	54 (2.6)	33 (5.5)	†
NOS	664 (31.7)	267 (44.4)	51 (40.5)
Ann Arbor Stage, <i>n</i> (%)			
I	509 (24.3)	105 (17.4)	49 (38.9)
II	524 (25.0)	121 (20.1)	25 (19.8)
III	572 (27.3)	161 (26.7)	34 (27.0)
IV	492 (23.5)	215 (35.7)	18 (14.3)
B symptoms, <i>n</i> (%)			
No	915 (43.6)	207 (34.4)	45 (35.7)
Yes	739 (35.2)	252 (41.9)	36 (28.6)
Unknown	443 (21.1)	143 (23.8)	45 (35.7)
<b>Geographic factors</b>			
Region, <i>n</i> (%)			
Northeast	480 (22.9)	151 (25.1)	28 (22.2)
Midwest	297 (14.2)	79 (13.1)	14 (11.1)
South	501 (23.9)	147 (24.4)	37 (29.4)
West	819 (39.1)	225 (37.4)	47 (37.3)
Urban/Rural, <i>n</i> (%)			
More populated	1855 (88.5)	530 (88.0)	113 (89.7)
Less populated	242 (11.5)	72 (12.0)	13 (10.3)
Hospital with chemotherapy, <i>n</i> (%)	2009 (95.8)	568 (94.4)	121 (96.0)

NOS, not otherwise specified.

\*No treatment refers to no claims for chemotherapy or RT.

†Cell counts &lt; 11 were suppressed and other cells were coarsened to avoid re-identification of patients in accordance with SEER-Medicare policy.

## References

- Abbasi, J. (2019) Older patients (still) left out of cancer clinical trials. *JAMA*, **322**, 1751.
- Aizer, A.A., Chen, M.H., McCarthy, E.P., Mendu, M.L., Koo, S., Wilhite, T.J., Graham, P.L., Choueiri, T.K., Hoffman, K.E., Martin, N.E., Hu, J.C. & Nguyen, P.L. (2013) Marital status and survival in patients with cancer. *Journal of Clinical Oncology*, **31**, 3869–3876.
- Appel, B.E., Chen, L., Buxton, A., Wolden, S.L., Hodgson, D.C. & Nachman, J.B. (2012) Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group. *Pediatric Blood & Cancer*, **59**, 1284–1289.
- Ballova, V., Ruffer, J.U., Haverkamp, H., Pfister, B., Muller-Hermelink, H.K., Duhmke, E., Worst, P., Wilhelmy, M., Naumann, R., Hentrich, M. & Engert, A. (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEA-COPP baseline and COPP-ABVD (study HD9elderly). *Annals of Oncology*, **16**, 124–131.
- Bjorkholm, M., Svedmyr, E. & Sjoberg, J. (2011) How we treat elderly patients with Hodgkin lymphoma. *Current Opinion in Oncology*, **23**, 421–428.
- Boll, B., Bredenfeld, H., Gorgen, H., Halbsguth, T., Eich, H.T., Soekler, M., Markova, J., Keller, U., Graeven, U., Kremers, S., Geissler, M., Trenn, G., Fuchs, M., von Tresckow, B., Eichenauer, D.A., Borchmann, P. & Engert, A. (2011) Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. *Blood*, **118**, 6292–6298.
- Boll, B., Goergen, H., Arndt, N., Meissner, J., Krause, S.W., Schnell, R., von Tresckow, B., Eichenauer, D.A., Sasse, S., Fuchs, M., Behringer, K., Klimm, B.C., Naumann, R., Diehl, V., Engert, A. & Borchmann, P. (2013) Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin study group. *Journal of Clinical Oncology*, **31**, 4431–4437.
- Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. & Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. *New England Journal of Medicine*, **327**, 1478–1484.
- Cassidy, A. (2012) Care for dual eligibles. *Health Affairs*, <https://doi.org/10.1377/hpb20120613.634976>.
- Connors, J.M., Jurczak, W., Straus, D.J., Ansell, S.M., Kim, W.S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K.J., Bartlett, N.L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P.L., Cunningham, D., Rosta, A., Josephson, N.C., Song, E., Sachs, J., Liu, R., Jolin, H.A., Huebner, D. & Radford, J.E. (2018) JECHELON-1 Study Group (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. *New England Journal of Medicine*, **378**, 331–344.
- Duggan, D.B., Petroni, G.R., Johnson, J.L., Glick, J.H., Fisher, R.I., Connors, J.M., Canellos, G.P. & Peterson, B.A. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. *Journal of Clinical Oncology*, **21**, 607–614.
- Engert, A., Ballova, V., Haverkamp, H., Pfister, B., Josting, A., Duhmke, E., Muller-Hermelink, K., Diehl, V. & German Hodgkin's Study Group (2005) Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. *Journal of Clinical Oncology*, **23**, 5052–5060.
- Evens, A.M., Sweetenham, J.W. & Horning, S.J. (2008) Hodgkin lymphoma in older patients: an uncommon disease in need of study. *Oncology (Williston Park)*, **22**, 1369–1379.
- Evens, A.M., Helenowski, I., Ramsdale, E., Nabhan, C., Karmali, R., Hanson, B., Parsons, B., Smith, S., Larsen, A., McKoy, J.M., Jovanovic, B., Gregory, S., Gordon, L.I. & Smith, S.M. (2012) A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. *Blood*, **119**, 692–695.
- Evens, A.M., Hong, F., Gordon, L.I., Fisher, R.I., Bartlett, N.L., Connors, J.M., Gascoyne, R.D., Wagner, H., Gospodarowicz, M., Cheson, B.D., Stiff, P.J., Advani, R., Miller, T.P., Hoppe, R.T., Kahl, B.S., Horning, S.J. & Horning, S.J. (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. *British Journal of Haematology*, **161**, 76–86.
- Evens, A.M., Advani, R.H., Helenowski, I.B., Fanale, M., Smith, S.M., Jovanovic, B.D., Bociek, G.R., Klein, A.K., Winter, J.N., Gordon, L.I. & Hamlin, P.A. (2018) Multicenter Phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. *Journal of Clinical Oncology*, **36**, 3015–3022.
- Feltl, D., Vitek, P. & Zamecnik, J. (2006) Hodgkin's lymphoma in the elderly: the results of 10 years of follow-up. *Leukaemia & Lymphoma*, **47**, 1518–1522.
- Forero-Torres, A., Holkova, B., Goldschmidt, J., Chen, R., Olsen, G., Boccia, R.V., Bordoni, R.E., Friedberg, J.W., Sharman, J.P., Palanca-Wessels, M.C., Wang, Y. & Yasnachak, C.A. (2015) Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. *Blood*, **126**, 2798–2804.
- Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W.J., Burke, G., McBurnie, M.A. & Cardiovascular Health Study Collaborative Research Group (2001) Frailty in older adults: evidence for a phenotype. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*, **56**, M146–156.
- Friedberg, J.W., Forero-Torres, A., Bordoni, R.E., Cline, V.J.M., Patel Donnelly, D., Flynn, P.J., Olsen, G., Chen, R., Fong, A., Wang, Y. & Yasnachak, C.A. (2017) Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged  $\geq 60$  years with HL. *Blood*, **130**, 2829–2837.
- Given, B. & Given, C.W. (2008) Older adults and cancer treatment. *Cancer*, **113**, 3505–3511.
- Gold, M.R., Jacobson, G.A. & Garfield, R.L. (2012) There is little experience and limited data to support policy making on integrated care for dual eligibles. *Health Aff (Millwood)*, **31**, 1176–1185.
- Gordon, L.I., Hong, F., Fisher, R.I., Bartlett, N.L., Connors, J.M., Gascoyne, R.D., Wagner, H., Stiff, P.J., Cheson, B.D., Gospodarowicz, M., Advani, R., Kahl, B.S., Friedberg, J.W., Blum, K.A., Habermann, T.M., Tuscano, J.M., Hoppe, R.T. & Horning, S.J. (2013) Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). *Journal of Clinical Oncology*, **31**, 684–691.
- Hoppe, R.T., Advani, R.H., Ai, W.Z., Ambinder, R.F., Aoun, P., Bello, C.M., Bierman, P.J., Blum, K.A., Chen, R., Dabaja, B., Duron, Y., Forero, A., Gordon, L.I., Hernandez-Ilizaliturri, F.J., Hochberg, E.P., Maloney, D.G., Mansur, D., Mauch, P.M., Metzger, M., Moore, J.O., Morgan, D., Moskowitz, C.H., Poppe, M., Pro, B., Winter, J.N., Yahalom, J., Sundar, H. & National Comprehensive Cancer Network (2012). Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. *Journal of National Comprehensive Cancer Network*, **10**, 589–597.
- Institute of Medicine (2003). In Smedley, B.D., Stith, A.Y. & Nelson, A.R. (Eds.), *Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care*. Washington, DC: National Academies Press (US).
- Jacobson, G., Neuman, T. & Damico, A. (2012) Medicare's role for dual eligible beneficiaries. *Medicare Policy*, <https://www.kff.org/wp-content/uploads/2013/01/8138-02.pdf>
- Kawachi, I., Daniels, N. & Robinson, D.E. (2005) Health disparities by race and class: why both matter. *Health Aff (Millwood)*, **24**, 343–352.
- Keating, N.L., Huskamp, H.A., Kouri, E., Schrag, D., Hornbrook, M.C., Haggstrom, D.A. & Landrum, M.B. (2018) Factors contributing to geographic variation in end-of-life expenditures for cancer patients. *Health Aff (Millwood)*, **37**, 1136–1143.
- Medicare Payment Advisory Committee & Medicaid and CHIP Payment and Access



- Commission (2018). *Beneficiaries Dually Eligible for Medicare and Medicaid*.
- Meyer, R.M., Gospodarowicz, M.K., Connors, J.M., Pearcey, R.G., Wells, W.A., Winter, J.N., Horning, S.J., Dar, A.R., Shustik, C., Stewart, D.A., Crump, M., Djurfeldt, M.S., Chen, B.E., Shepherd, L.E. & NCIC Clinical Trials Group, Eastern Cooperative Oncology Group (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. *New England Journal of Medicine*, **366**, 399–408.
- National Cancer Institute. SEER-medicare linked database. Retrieved 10/1/2019, from <https://healthcaredelivery.cancer.gov/seermedicare/>.
- National Cancer Institute. Surveillance Epidemiology and End Results Program. Health Service Areas (HSA). Retrieved 9/25/2019, from: <https://seer.cancer.gov/seerstat/variables/countyattribs/hsa.html><https://seer.cancer.gov/seerstat/variables/countyattribs/hsa.html>.
- National Comprehensive Cancer Network (2019). Clinical Practice Guidelines in Oncology. Hodgkin Lymphoma. NCCN Evidence Blocks. Version 1.2019. Retrieved August 7, 2019, from [https://www.nccn.org/professionals/physician\\_gls/pdf/hodgkin\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hodgkin_blocks.pdf).
- Neuman, P. & Jacobson, G.A. (2018) Medicare advantage checkup. *New England Journal of Medicine*, **379**, 2163–2172.
- Onega, T., Duell, E.J., Shi, X., Wang, D., Demidenko, E. & Goodman, D. (2008) Geographic access to cancer care in the U.S. *Cancer*, **112**, 909–918.
- Parikh, R.R., Grossbard, M.L., Green, B.L., Harrison, L.B. & Yahalom, J. (2015) Disparities in survival by insurance status in patients with Hodgkin lymphoma. *Cancer*, **121**, 3515–3524.
- Popescu, I., Schrag, D., Ang, A. & Wong, M. (2016) Racial/ethnic and socioeconomic differences in colorectal and breast cancer treatment quality: the role of physician-level variations in care. *Medical Care*, **54**, 780–788.
- Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.C., Saunders, L.D., Beck, C.A., Feasby, T.E. & Ghali, W.A. (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Medical Care*, **43**, 1130–1139.
- Reagan, P.M., Magnuson, A. & Friedberg, J.W. (2016) Hodgkin lymphoma in older patients. *American Journal of Hematology/Oncology*, **12**, 13–19.
- Research Data Assistance Center (2017) CMS Cell Size Suppression Policy. Retrieved 1/2/2020, from <https://www.resdac.org/articles/cms-cell-size-suppression-policy>.
- Santoro, A., Bonadonna, G., Valagussa, P., Zucali, R., Viviani, S., Villani, F., Pagnoni, A.M., Bonfante, V., Musumeci, R., Crippa, F. & Tess, J.T. (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. *Journal of Clinical Oncology*, **5**, 27–37.
- Segal, J.B., Chang, H.Y., Du, Y., Walston, J.D., Carlson, M.C. & Varadhan, R. (2017) Development of a claims-based frailty indicator anchored to a well-established frailty phenotype. *Medical Care*, **55**, 716–722.
- Social Security (1965) State plans for medical assistance. In: Sec. 1902. [42 U.S.C. 1396a].
- The Kaiser Commission on Medicaid and the Uninsured (2010). Chronic disease and comorbidity among dual eligibles: implications for patterns of medicaid and medicare service use and spending.
- Warren, J.L., Klabunde, C.N., Schrag, D., Bach, P.B. & Riley, G.F. (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. *Medical Care*, **40**(Suppl. 8), IV-3-18. <https://doi.org/10.1097/01.MLR.0000020942.47004.03>.
- Warren, J.L., Butler, E.N., Stevens, J., Lathan, C.S., Noone, A.M., Ward, K.C. & Harlan, L.C. (2015) Receipt of chemotherapy among medicare patients with cancer by type of supplemental insurance. *Journal of Clinical Oncology*, **33**, 312–318.
- Zhang, A.Y. & Siminoff, L.A. (2003) The role of the family in treatment decision making by patients with cancer. *Oncology Nursing Forum*, **30**, 1022–1028.